Leaderboards/endometrial and cervical cancer treatments

endometrial and cervical cancer treatments

Last updated June 2, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Nadeem R. Abu‐Rustum
Memorial Sloan Kettering Cancer Center
99
2
Vaishnavi Sambandam
National Comprehensive Cancer Network
90
3
Rebecca Kristeleit
King's College London
50
4
Rowan Miller
Queen Mary University of London
40
5
Chaiyawut Paiboonborirak
Bangkok Metropolitan Administration
30
6
Sarikapan Wilailak
Mahidol University
20

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Jonathan S. Berek
Stanford Cancer Institute
90
2
Tullio Golia D’Augè
Policlinico Umberto I
80
3
Guangyu Wang
Chinese Academy of Medical Sciences & Peking Union Medical College
70
4
Sandip Pravin Patel
University of California San Diego
60
5
Wafa Khadraoui
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
50
6
Dimitrios Stefanoudakis
National and Kapodistrian University of Athens
40
7
Eleftheria Kalogera
Mayo Clinic
30
8
Giovanna Cocomazzi
Casa Sollievo della Sofferenza
20
9
Nehal J. Lakhani
South Texas Accelerated Research Therapeutics
10

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Sameek Roychowdhury
The Ohio State University
90
2
Cristiana Sessa
Institute of Oncology Research
80
3
José Baselga
Hebron University
70
4
C. Sessa
Institute of Oncology Research
60
5
Arno J. Mundt
University of California, San Diego
50
6
Neville F. Hacker
Royal Hospital for Women
30
7
Deborah Watkins Bruner
Summa Health System
20
8
Rodney H. Reznek
St Bartholomew's Hospital
10

All-Time Leaders Papers

1
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
New England Journal of Medicine|2015
1.7k cit.
2
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology|2011
684 cit.
3
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
Oncogene|2011
534 cit.
4
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
Journal of Clinical Oncology|2014
370 cit.

Reagents for endometrial and cervical cancer treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Agilent/Dako

p53 Tumor Suppressor Protein

#M7001
View Evidence →Cell Signaling Technology

CAPZB (E4H6C) Rabbit Monoclonal Antibody

#10333$161
View Evidence →Cell Signaling Technology

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody (Pacific Blue™ Conjugate)

#75864$493
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Progesterone Receptor

Cited in 5 papers
#M3569
View Evidence →Proteintech

PAX8 antibody

Cited in 5 papers
#10336-1-AP$449
View Evidence →Cell Signaling Technology

FnCpf1/Cas12a (Strain U112) (E7I2B) Rabbit Monoclonal Antibody

#90111$161
View Evidence →